---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-23-001714"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T16:55:24.900765+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Entera Bio Q1 net loss $2.2M vs $3.8M YoY; cash $10.7M into Q3 2024

## Summary
- Net loss of $2.2M, $0.08 per share, compared to $3.8M, $0.13 per share in Q1 2022.
- Cash and equivalents $10.7M as of Mar 31, 2023; expects cash to fund ops into Q3 2024.
- R&D expenses $0.9M (down 47% YoY); G&A expenses $1.3M (down 41% YoY).
- Plans to initiate PK study of oral PTH(1-34) for hypoparathyroidism H1 2023, topline H2 2023.
- Amgen research collaboration discontinued by mutual agreement after 4+ years.

## SEC filing metadata
- accession: 0001178913-23-001714
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891323001714/0001178913-23-001714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891323001714/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-23-001714
- JSON: https://secwatch.observer/filing/0001178913-23-001714.json
- Plain text: https://secwatch.observer/filing/0001178913-23-001714.txt

## Key facts
- Earnings Releases
  Entera Bio Ltd. reported first quarter ended March 31, 2023 results: net income Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023, EPS $0.08 per ordinary share (basic and diluted).
  - Period: first quarter ended March 31, 2023
  - Net income: Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023
  - EPS: $0.08 per ordinary share (basic and diluted)
  - Result: reported results
  source text: Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891323001714/0001178913-23-001714-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.